Canon Kabushiki Kaisha

Toray Industries, Inc.

Kyoto University

Kabushiki Kaisha Yakult Honsha

Afi Corporation

Japan Breast Cancer Research Group

Masakazu Toi

Toshiyuki Kitai

Satoko Kozono

Toshinobu Tokita

Katsuya Oikawa

Seigo Nakamura

Yasuo Ohashi

Kazuharu Shimizu

Fumiaki Sato

Yoshiko Wada

Gozoh Tsujimoto

Yoshikazu Wakizaka

Hitoshi Tsuda

Akira Myomoto

Takaharu Enjoji

Takayuki Ueno

Masayo Takano

Futoshi Akiyama

Takayuki Itoi

Zhipeng Wang

Tomomi Nishimura

Hiroji Iwata

Katsumasa Kuroi

Shinji Ohno

Norikazu Masuda

Kenjiro Aogi

Nobuaki Sato

Masafumi Kurosumi

An analysis device () analyzes a crossover frequency at which a dielectrophoretic force on dielectric particles switches from a repulsive force to an attractive force or from the attractive force to the repulsive force, comprising a flow channel (), a pair of electrodes (), a power supply (), an imaging unit () and an analyzer (). Through the flow channel (), a sample solution containing the dielectric particles in the dielectrophoretic liquid flows. The pair of electrodes () are arranged in the first channel. The power supply () applies a frequency-modulated AC voltage to the first electrodes (). The imaging unit () captures an image of a movement trajectory of each of the dielectric particles flowing between the electrodes () in the flow channel. The analyzer () obtains the crossover frequency of the dielectric particles based on the captured image of the movement trajectory.

Analysis device and separation device

The present invention provides a subject information accumulating apparatus that conducts diagnosis with high reliability. The subject information accumulating apparatus includes compression plates configured to compress a subject, an irradiation unit configured to apply light, an acoustic wave detector configured to receive acoustic waves generated within a subject and to output an electric signal, and a controller configured to perform control so that an acoustic wave image and pressure information are displayed on a display unit.

Subject information accumulating apparatus

This invention relates to a composition and a method for prediction of a response to Trastuzumab therapy in a breast cancer patient, and more specifically, a composition, a kit, a DNA chip, and a method for predicting a response to Trastuzumab therapy by using polynucleotides each comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 9, 11 to 19, and 21 to 23 in the Sequence Listing or a nucleotide sequence derived therefrom by substitution of u with t, mutants thereof, derivatives thereof, or fragments thereof comprising at least 16 continuous nucleotides, or a polynucleotide comprising a complementary sequence thereof, and using an increase or decrease in Her2 protein expression level as an indicator.

Method for predicting response to trastuzumab therapy in breast cancer patients

A subject information acquisition device includes a first holding member that holds a subject of a patient, a first probe that detects an acoustic wave having propagated through the first holding member and that performs a scanning operation, a first holding-member support located on a patient side from a scanning range of the first probe and that reduces bending of the first holding member, and a second probe located on the patient side from the scanning range of the first probe.

Subject information acquisition device

An administration method comprising: determining a cancer type through (i) first data indicating that an Estrogen Receptor (ER) is negative and a Human Epidermal growth factor Receptor-2 (Her2) is negative, or (ii) second data indicating that at least one of the ER and the Her2 is positive; and when the cancer type is determined through (i) the first data indicating that the ER is negative and the Her2 is negative: first performing a docetaxel administration cycle comprising administrating docetaxel to a patient multiple times at certain intervals; and then performing a 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) administration cycle comprising administrating 5-fluorouracil, epirubicin, and cyclophosphamide to the patient multiple times at certain intervals, and when the cancer type is determined through (ii) the second data indicating that at least one of the ER and Her2 is positive: first performing the FEC administration cycle; and then performing the docetaxel administration cycle.

Method for the administration of anti-cancer drugs

Provided is an agent or a food or drink for reducing the risk of developing breast cancer. An agent for reducing the risk of developing breast cancer which comprises a composition containing living cells of

Agent for reducing risk of developing cancer

Growing community of inventors

Kyoto, Japan

Masakazu Toi